Glycylcyclines: third-generation tetracycline antibiotics.
Although tetracycline antibiotics have some roles in human and veterinary medicine, the widespread emergence of microbial resistance has severely limited their effectiveness. A new generation of tetracyclines, the glycylcyclines, is being specifically developed to overcome problems of resistance to earlier tetracyclines. One of the glycylcyclines, 9-t-butylglycylamido-minocycline (GAR-936, tigilcycline), is currently undergoing clinical trials and microbiological, pharmacodynamic and pharmacokinetic data have recently been presented for several glycylcyclines, including GAR-936. An ongoing concern is whether resistance to glycylcyclines might arise in the future.
Chopra
I
I
Antimicrobial Research Centre and Division of Microbiology, School of Biochemistry and Molecular Biology, University of Leeds, UK. i.chopra@leeds.ac.uk
D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D013678:Technology, Pharmaceutical / Q000379:methods; D013753:Tetracycline Resistance / Q000235:genetics; D013754:Tetracyclines / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D013754:Tetracyclines; C087533:CL 331002